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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 11, Revision 2 
(FGE.11Rev2): 
Aliphatic dialcohols, diketones, and hydroxyketones from chemical groups 
8 and 101 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
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SUMMARY 
The Scientific Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) was asked to provide scientific advice to the Commission on the implications for human health 
of chemically defined flavouring substances used in or on foodstuffs in the Member States. In 
particular, the Panel was requested to evaluate 12 flavouring substances in the Flavouring Group 
Evaluation 11, Revision 2 (FGE.11Rev2), using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000. These 12 flavouring substances belong to chemical group 10, Annex I 
of the Commission Regulation (EC) No 1565/2000. 
The present flavouring group includes 12 candidate substances; nine alpha-diketones or their 
corresponding alcohols or ketals [FL-no: 02.133, 06.134, 07.071, 07.152, 07.167, 07.168, 07.238, 
07.248 and 07.260], and three beta-diketones or their corresponding hydroxyketones (of which one is 
a tertiary alcohol) [FL-no: 07.097, 07.165 and 07.184] all belonging to chemical groups 8 and 10. 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2009-00563, adopted on 17 June 2009. 
2  Panel members Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
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Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, Detlef 
Wölfle. Correspondence: cef-unit@efsa.europa.eu  
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Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, 
Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the 
preparatory work on this scientific Opinion. 
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One of the 12 candidate substances possesses four chiral centres [FL-no: 06.134] two possesses two 
chiral centres [FL-no: 02.133 and 07.168] and four substances possesses one chiral centre [FL-no: 
07.097, 07.167, 07.184 and 07.238]. One of the substances [FL-no: 07.260] is a mixture of four 
isomers. 
Five of the candidate substances are classified into structural class I, six are classified into structural 
class II and one is classified into structural class III.  
Eight of the 12 candidate substances in the present group have been reported to occur naturally in a 
wide range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the 12 candidate substances have European daily per capita 
intakes ranging from 0.0012 to 15 microgram, which are below the thresholds of concern for structural 
class I, II and III (1800, 540 and 90 microgram/person/day, respectively). 
The candidate substance 3-methyl-2,4-nonadione [FL-no: 07.184] contains a structural 2,4-dione 
element similar to pentan-2,4-dione. The only genotoxicity data available for this substance was a 
valid unpublished GLP study in S. typhimurium and E. coli which were both negative. Similar 
negative result was obtained for pentan-2,4-dione in a valid GLP study in Salmonella, however, 
positive genotoxicity results were obtained in other studies both in vitro and in vivo. Due to this 
anticipated structural alert for genotoxicity (the 2,4-dione structure) the Procedure was not applied for 
3-methyl-2,4-nonadione [FL-no: 07.184] and accordingly additional data on genotoxicity are required. 
For the remaining candidate substances, genotoxicity data are only available for a limited number of 
substances, and the genotoxicity could not be assessed adequately. However, the genotoxicity data 
available on these remaining 11 candidate substances do not preclude evaluation using the Procedure. 
Ten of the 11 flavouring substances evaluated through the Procedure are expected to be metabolised to 
innocuous products. 
For the remaining candidate substance evaluated through the Procedure, diacetyl-trimer [FL-no: 
06.134] the data available do not allow to anticipate hydrolysis to innocuous products. No No 
Observed Adverse Effect Level (NOAEL) exists for the substance or a structurally related substance to 
provide an adequate margin of safety under the conditions of intended use and accordingly additional 
data are required. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
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It is considered that on the basis of the default MSDI approach the ten of the 11 candidate substances 
evaluated through the Procedure [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 
07.238, 07.248 and 07.260] would not give rise to safety concerns at the estimated levels of intake 
arising from their use as flavouring substances. 
When the estimated intakes were based on the mTAMDI they ranged from 1600 to 3900 
microgram/person/day for the five candidate substances from structural class I. For one of these 
candidate substances [FL-no: 02.133] the estimated intake is above the threshold of concern of 1800 
microgram/person/day for structural class I. For the six candidate substances, which are assigned to 
structural class II, the estimated intake based on the mTAMDI range from 1500 to 5400 microgram/ 
person/day, which is above the threshold of concern for structural class II of 540 
microgram/person/day. For the one candidate substance [FL-no: 07.168] from structural class III the 
mTAMDI value is 1600 microgram/person/day, which exceeds the threshold of concern for structural 
class III of 90 microgram/person/day. The four candidate substances [FL-no: 07.097, 07.165, 07.167, 
07.238], which have mTAMDI intake estimates below the threshold of concern for structural class I 
are also expected to be metabolised to innocuous products. 
Thus, for seven of the 11 candidate substances evaluated through the Procedure [FL-no: 02.133, 
06.134, 07.071, 07.152, 07.168, 07.248 and 07.260] the intakes, estimated on the basis of the 
mTAMDI exceed the threshold for the structural class, to which the flavouring substances have been 
assigned. Therefore, more reliable exposure data are required. On the basis of such additional data, the 
substances should be reconsidered along the steps of the Procedure. Following this procedure 
additional toxicological data might become necessary. 
In order to determine whether the conclusion for the candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. The stereoisomeric 
compositions have not been specified for three of the substances [FL-no: 06.134,  07.184 and 07.260]. 
One of the substances [FL-no: 07.260] is a mixture of four isomers (three positional isomers, where 
one of these can exists as two stereoisomers) and the composition of mixture is not specified. 
Furthermore, for [FL-no: 07.097] the minimum assay is too low, so information on secondary 
components of [FL-no: 07.097] is missing.  
Thus, the final evaluation of the materials of commerce cannot be performed for four substances [FL-
no: 06.134, 07.097, 07.184 and 07.260], pending further information. For the candidate substance 
diacetyl-trimer [FL-no: 06.134] additional metabolism/toxicity data are required, and for 3-methyl-
2,4-nonadione [FL-no: 07.184] data on genotoxicity are required before it can be evaluated through 
the Procedure. 
The remaining eight substances [FL-no: 02.133, 07.071, 07.152, 07.165, 07.167, 07.168, 07.238 and 
07.248] would present no safety concern at the levels of intake estimated on the basis of the MSDI 
approach. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the chemical groups evaluated in 
this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION 
FGE Opinion 
adopted by 
EFSA 
Link No. of 
candidate 
substances 
FGE.11 9 December 2004 http://www.efsa.europa.eu/en/science/afc/afc_opinions/815.html 6 
FGE.11Rev1 17 April 2007 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902220233.htm 
7 
FGE.11Rev2 17 June 2009  12 
The present Revision of FGE.11, FGE.11Rev2, includes the assessment of five additional candidate 
substances [FL-no: 06.134, 07.097, 07.168, 07.184 and 07.248]. Genotoxicity data are available for 
[FL-no: 06.134 and 07.184]. Metabolism data are available for [FL-no: 06.134]. 
One flavouring substance, pentan-2,4-dione (former [FL-no: 07.191]) was deleted from the Register of 
flavouring substances as it is considered genotoxic in vitro and in vivo. Accordingly, its use as 
chemically defined flavouring substance is toxicologically not acceptable.  
The genotoxic potential of the alpha-beta unsaturated ketone 2-hydroxypiperitone [FL-no: 07.168] 
was evaluated in FGE.213 with respect to genotoxic potential. In FGE.213, 3-ethyl-2-hydroxy-2-
cyclopenten-1-one [FL-no: 07.057] was considered representative for nine structurally related 
substances in FGE.213, among those 2-hydroxypiperitone [FL-no: 07.168]. No carcinogenicity was 
observed for 3-ethyl-2-hydroxy-2-cyclopenten-1-one [FL-no: 07.057] in rats. The Panel concluded 
that the structural alert for genotoxicity is overruled for 3-ethyl-2-hydroxy-2-cyclopenten-1-one [FL-
no: 07.057] as well as for the nine structurally related substances (EFSA, 2009x). The Panel therefore 
concluded that 2-hydroxypiperitone [FL-no: 07.168] could be evaluated through the Procedure in 
FGE.11Rev2. 
Flavouring Group Evaluation 11, Revision 2
 
 
6 EFSA Journal 2011; 9(2):1170 
Cyclic alpha,beta-diketones as 2-hydroxypiperitone [FL-no: 07.168] has been evaluated with other 
FGE.19 substances, as they are in equlibrium with enolic forms, which are alpha,beta-unsaturated 
ketones. However, in the case of the acyclic alpha,beta-diketones in this evaluation, the enolic form is 
not significant, consequently these substances were not taken to FGE.19. 
Since the publication of FGE.11Rev1 and the Minutes from the 7th Plenary meeting in which the 
conclusion on the FGE.11Rev2 was summarised, information on stereoisomeric composition and a 
boiling point has been provided by EFFA on the following six substances: [FL-no: 02.133, 07.097, 
07.167, 07.168, 07.238 and 07.260] (EFFA, 2010a). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 
evaluation programme. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 11, Revision 2 
1.1. Description 
The present Flavouring Group Evaluation 11, Revision 2 (FGE.11Rev2), using the Procedure as 
referred to in the Commission Regulation (EC)No 1565/2000 (the Procedure – shown in schematic 
form in Annex I), deals with nine alpha-diketones or their corresponding alcohols or ketal and one 
beta-diketone and two beta-hydroxyketones. These 12 flavouring substances (candidate substances) 
belong to chemical groups 8 and 10 of Annex I of Regulation (EC) No 1565/2000 (EC, 2000a). 
One flavouring substance, pentan-2,4-dione (former [FL-no: 07.191]) was deleted from the Register of 
flavouring substances as it is considered genotoxic in vitro and in vivo. 
The 12 candidate substances under consideration in the present evaluation are listed in Table 1, as well 
as their chemical Register names, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of 
Europe- (CoE-) and Flavor and Extract Manufacturers Association- (FEMA-) numbers, structures and 
specifications. This group of candidate substances includes nine alpha-diketones or their 
corresponding alcohols or ketals [FL-no: 02.133, 06.134, 07.071, 07.152, 07.167, 07.168, 07.238, 
07.248 and 07.260], and three beta-diketones or their corresponding alcohols (of which one is a 
tertiary alcohol) [FL-no: 07.097, 07.165 and 07.184]. 
The outcome of the safety evaluation is summarised in Table 2a. 
The hydrolysis products anticipated for the candidate ketals are listed in Table 2b. 
The 12 candidate substances are closely related structurally to 13 aliphatic acyclic alpha-diketones and 
related alpha-hydroxyketones (supporting substances) evaluated at the 51st meeting of the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) in the group “Aliphatic acyclic and 
alicyclic alpha-diketones and related alpha-hydroxyketones” (JECFA, 1999a). The names and 
structures of the 13 supporting substances are listed in Table 3, together with their evaluation status. 
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1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number, etc.). 
One of the 12 candidate substances possesses four chiral centres [FL-no: 06.134] two possess two 
chiral centres [FL-no: 02.133 and 07.168] and four substances possess one chiral centre [FL-no: 
07.097, 07.167, 07.184 and 07.238]. The stereoisomeric compositions have not been specified for 
three of these substances [FL-no: 06.134, 07.184 and 07.260]. One of the substances [FL-no: 07.260] 
is a mixture of four isomers (three positional isomers, where one of these can exists as two 
stereoisomers) and the composition of mixture is not specified. 
1.3. Natural Occurrence in Food 
Eight of the 12 candidate substances have been reported to occur in fruits, fruit juice, vegetables, 
bread, cheese, fish, meat, peanuts, cocoa, wine, drinks, beer, tea, and coffee. Quantitative data on the 
natural occurrence in food have been reported for five of these substances (TNO, 2000; EFFA, 2004x; 
Flavour Industry, 2005b)). 
These reports are: 
• Butane-2,3-diol [FL-no: 02.133]: 0.006 mg/kg in fish (lean), up to 90 mg/kg in cheddar 
cheese, up to 2.3 mg/kg in raspberry, up to 850 mg/kg in vinegar, 1.9 mg/kg in sherry and up 
to 2900 mg/kg in various types of wine. 
• 3,3-Diethoxybutan-2-one [FL-no: 07.152]: up to 0.1 mg/kg in cognac and weinbrand. 
• 4-Hydroxy-4-methylpentan-2-one [FL-no: 07.165]: up to 0.07 mg/kg in roasted chicken. 
• 2-Hydroxypiperitone [FL-no: 07.168]: 36 mg/kg in black currant (buds). 
• Octan-2,3-dione [FL-no: 07.248]: 0.1 mg/kg in fish (lean), up to 0.2 mg/kg in turkey (roasted), 
up to 0.07 in chicken (roasted), up to 0.112 mg/kg in Guinea hen, up to 0.03 mg/kg in beef 
(grilled, roasted), up to 108 mg/kg in lamb and mutton fat (heated), 0.01 mg/kg in peanuts.  
According to TNO four of the substances, diacetyl-trimer [FL-no: 06.134], 3-(hydroxymethyl)octan-2-
one [FL-no: 07.097], 3-hydroxy-2-octanone [FL-no: 07.238] and 1- or 3-hydroxy-5-methyl-2- or 3-
hexanone [FL-no: 07.260] have not been reported to occur naturally in any food items (TNO, 2000). 
2. Specifications 
Purity criteria for the 12 candidate substances have been provided by the Flavour Industry (EFFA, 
2003e; EFFA, 2004x; EFFA, 2007l; EFFA, 2010a; Flavour Industry, 2005a; Flavour Industry, 2005b) 
(see Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), specification of secondary components is needed for [FL-no: 07.097] (see Table 1). 
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Information on stereoisomerism/composition of mixture is needed for three substances [FL-no: 
06.134,  07.184, and 07.260] (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the “Maximised Survey-derived Daily Intake” (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for 
the enlarged EU. 
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estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the present Flavouring Group Evaluation, Revision 2 (FGE.11Rev2) the total annual volume of 
production of the seven candidate substances for use as flavouring substances in Europe has been 
reported to be approximately 180 kg (EFFA, 2003f; EFFA, 2004x; EFFA, 2007l; Flavour Industry, 
2005a; Flavour Industry, 2005b). 120 kg is accounted for by 3-(hydroxymethyl)octan-2-one [FL-no: 
07.097] and 25 kg is accounted for by butane-2,3-diol [FL-no: 02.133], 19 kg is accounted for by 1- or 
3-hydroxy-5-methyl-2- or 3-hexanone [FL-no: 07.260] and 10 kg is accounted for by diacetyl-trimer 
[FL-no: 06.134]. For the 13 supporting substances the total annual volume of production has been 
reported by JECFA to be approximately 38000 kg. Diacetyl [FL-no: 07.052] accounts for 18000 kg 
and 3-hydroxybutan-2-one [FL-no: 07.051] accounts for 19000 kg (JECFA, 2000a). 
On the basis of the annual volumes of production reported for the 12 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated (Table 2a). The estimated daily 
per capita intake of 3-(hydroxymethyl)octan-2-one [FL-no: 07.097], butane-2,3-diol [FL-no: 02.133], 
1- or 3-hydroxy-5-methyl-2 or 3-hexanone [FL-no: 07.260] and diacetyl-trimer [FL-no: 06.134] from 
use as a flavouring substance is 15, 3.0 microgram, 2.3 microgram and 1.2 microgram, respectively. 
The daily per capita intakes for each of the remaining substances are less than 0.37 microgram (Table 
2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the 12 candidate substances, information on food categories and normal 
and maximum use levels5,6,7 were submitted by the Flavour Industry (EFFA, 2003e; EFFA, 2003f; 
EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b; EFFA, 2007a; EFFA, 2007l).  
The 12 candidate substances are used in flavoured food products divided into the food categories, 
outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000a), as shown in 
Table 3.1. For the present calculation of mTAMDI, the reported normal use levels were used. In the 
case where different use levels were reported for different food categories the highest reported normal 
use level was used. 
According to the Flavour Industry, the normal use levels for the candidate substances are in the range 
of 1 – 20 mg/kg food, and the maximum use levels are in the range of 5 - 100 mg/kg (EFFA, 2003e; 
EFFA, 2003f; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b; EFFA, 2007l) (See 
Table II.1.2, Appendix II).  
The mTAMDI values for the five candidate substances from structural class I (see Section 5) range 
from 1600 to 3900 microgram/person/day. For the six candidate substances from structural class II the 
mTAMDI values range from 1500 to 5400 microgram/person/day. For the one candidate substance 
[FL-no: 07.168] from structural class III the mTAMDI value is 1600 microgram/person/day. 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
Table 3.1 Use of Candidate Substances 
Food 
categor
y 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All 12  
02.0 Fats and oils, and fat emulsions (type water-in-oil) All 12 except [FL-no: 
07.260] 
03.0 Edible ices, including sherbet and sorbet All 12  
04.1 Processed fruits All 12 except [FL-no: 
06.134] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Only [FL-no: 07.260] 
05.0 Confectionery All 12  
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, 
pulses & legumes, excluding bakery 
All 12 except [FL-no: 
07.260] 
07.0 Bakery wares All 12  
08.0 Meat and meat products, including poultry and game All 12 except [FL-no: 
06.134, 07.260] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All 12 except [FL-no: 
06.134, 07.260] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All 12 except [FL-no: 
07.260] 
13.0 Foodstuffs intended for particular nutritional uses All 12 except [FL-no: 
06.134, 07.260] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 12  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All 12  
15.0 Ready-to-eat savouries All 12 except [FL-no: 
07.260] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could 
not be placed in categories 1 – 15 
All 12 except [FL-no: 
07.260] 
4. Absorption, Distribution, Metabolism and Elimination 
Ketals are expected to be readily hydrolysed after ingestion under the acidic conditions in the stomach 
to the corresponding alcohols and ketones.  
In vitro studies conducted with diacetyl-trimer [FL-no: 06.134] showed 100 % disappearance within 
12 hours in simulated gastric juice and 75 % disappearance in artificial saliva at pH 9 within 45 
minutes (Guentert, 2004). However, no data on the identities of the hydrolysis products formed in 
these studies were provided. For the candidate substance diacetyl-trimer [FL-no: 06.134] (1,1’-
(tetrahydro-6a-hydroxy-2,3a,5-trimethylfuro[2,3-d]-1,3-dioxole-2,5-diyl)bis-ethanone) the hydrolysis 
products anticipated under the acidic conditions in the stomach are equimolar amounts of diacetyl and 
3-hydroxy-3-methyl-hept-2,5,6-trione (Table 2b). 
The candidate substances, which are alpha- and beta-diketones, ketal, hydroxyketones or diols, are 
expected to be absorbed from the gastrointestinal tract. The metabolic fate of acyclic aliphatic 
diketones depends primarily on the position of the carbonyl function and the chain length. Aliphatic 
acyclic diketones and alpha-hydroxyketones which contain a carbonyl function at the 2-position (i.e. a 
methyl ketone) may undergo alpha–hydroxylation and subsequent oxidation of the terminal methyl 
group to eventually yield corresponding ketocarboxylic acids. The ketoacids are intermediary 
metabolites (e.g. alpha-ketoacids), which may undergo oxidative decarboxylation to yield carbon 
dioxide and an aliphatic carboxylic acid. The acid may be completely metabolised in the fatty acid 
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pathway and citric acid cycle. Beta-keto-acids and derivatives readily undergo decarboxylation. Along 
with alpha-keto- and alpha-hydroxyacids, they yield breakdown products, which are incorporated into 
normal biochemical pathways  
Alternatively, the methyl-substituted diketones may be successively reduced to the corresponding 
hydroxyketones and diols, which are excreted in the urine as glucuronic acid conjugates. This pathway 
is favoured at elevated in vivo concentrations, especially for longer chain length ketones. Alpha-
hydroxyketones or their diol metabolites may be excreted as glucuronic acid conjugates. If the 
carbonyl function is located elsewhere on the chain or in a ring, reduction is the predominant 
detoxification pathway. 
A more detailed discussion on the metabolism of these alpha-, beta-diketones, a related ketal, 
hydroxyketones and diols follows in Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
In FGE.11, one of the six candidate substances, pentan-2,4-dione, was, based on the genotoxicity data 
available, considered genotoxic in vitro and in vivo and accordingly, the Procedure was not applied for 
this substance. The new candidate substance 3-methyl-2,4-nonadione [FL-no: 07.184] contains a 
structural 2,4-dione element similar to pentan-2,4-dione. The only genotoxicity data available for this 
substance are two valid un-published GLP studies in Salmonella typhimurium and Escherichia coli 
which were negative. A similar negative result was obtained for 2,4-pentandione in a valid GLP study 
in S. typhimurium, however, positive genotoxicity results were obtained in other studies both in vitro 
and in vivo. Due to these data the Procedure was not applied to 3-methyl-2,4-nonadione [FL-no: 
07.184] and accordingly additional data on genotoxicity are required. 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the remaining 11 candidate substances from chemical groups 8 and 10 the 
Procedure was applied. The stepwise evaluations are summarised in Table 2a. 
Step 1 
Five of the candidate substances [FL-no: 02.133, 07.097, 07.165, 07.167 and 07.238], are classified 
into structural class I according to the decision tree approach presented by Cramer et al. (Cramer et al., 
1978). Five of the candidate substances are classified into structural class II [FL-no: 06.134, 07.071, 
07.152, 07.248 and 07.260] and the remaining substance [FL-no: 07.168] is classified into structural 
class III.  
Step 2 
Ketals are expected to be readily hydrolysed after ingestion under the acid conditions in the stomach 
to the corresponding alcohols and ketones.  
For the candidate substance diacetyl-trimer [FL-no: 06.134] (1,1’-(tetrahydro-6a-hydroxy-2,3a,5-
trimethylfuro[2,3-d]-1,3-dioxole-2,5-diyl)bis-ethanone), anticipated hydrolysis products under the 
acidic conditions in the stomach are equimolar amounts of diacetyl and 3-hydroxy-3-methyl-hept-
2,5,6-trione. In vitro studies conducted with diacetyl-trimer [FL-no: 06.134] in simulated gastric juice 
showed 100 % disappearance within 12 hours. Similar studies conducted in artificial saliva showed 75 
% disappearance of diacetyl-trimer at pH 9 within 45 minutes (Guentert, 2004). However, no data on 
the identities of the hydrolysis products formed in these studies were provided. Therefore, the Panel 
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did not consider the data sufficient to conclude that this substance is hydrolysed to innocuous products 
and the evaluation of this substance accordingly proceeds via the B-side of the Procedure. 
At the estimated levels of intake, the remaining ten candidate substances would not be expected to 
saturate metabolic detoxification pathways. They are considered to be metabolised to innocuous 
products. The evaluation of these ten candidate substances, therefore, proceeds via the A-side of the 
Procedure scheme (Annex I).  
Step A3 
The estimated levels of intake for the five candidate substances classified into structural class I are in 
the range of 0.0012 - 15 microgram/capita/day, which are below the human intake threshold of 
concern for structural class I (1800 microgram/person/day). The intakes of the four class II candidate 
substances evaluated through the B-side of the Procedure are 0.0012 – 2.3 microgram/capita/day, 
which also are below the human intake threshold for that class (540 microgram/person/day). The 
intake of the one class III candidate substance [FL-no: 07.168] is 0.0012 microgram/capita/day, which 
is below the human intake threshold for that class (90 microgram/person/day) (Table 2a).  
Based on the results of the safety evaluation sequence of the Procedure, these ten candidate substances 
proceeding via the A-side of the Procedure scheme do not pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on MSDI approach. 
Step B3 
The estimated level of intake for the candidate substance diacetyl-trimer [FL-no: 06.134] classified 
into structural class II is 1.2 microgram/capita/day, which is below the human intake threshold for 
structural class II (540 microgram/person/day). 
Step B4 
No NOAEL exists for diacetyl-trimer [FL-no: 06.134] or a structurally related substance to provide an 
adequate margin of safety under the conditions of intended use and accordingly additional data are 
required.  
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for the five candidate substances in structural class I based on the mTAMDI 
approach range from 1600 to 3900 microgram/person/day. For one of the substances the mTAMDI 
value is above the threshold of concern for structural class I of 1800 microgram/person/day. For 
comparison of the intake estimate based on the MSDI approach and mTAMDI approach see Table 6.1. 
The estimated intakes for the six candidate substances assigned to structural class II based on the 
mTAMDI range from 1500 to 5400 microgram/person/day, which are above the threshold of concern 
for structural class II substances of 540 microgram/person/day. For comparison of the MSDI- and 
mTAMDI values, see Table 6.1. 
The estimated intake for the one candidate substance 2-hydroxypiperitone [FL-no: 07.168] assigned to 
structural class III based on the mTAMDI is 1600 microgram/person/day, which is above the threshold 
of concern for structural class III substances of 90 microgram/person/day. For comparison of the 
MSDI and mTAMDI values see Table 6.1. 
So, for eight of the 12 candidate substances further information is required. This would include more 
reliable intake data and then, if required, additional toxicological data. 
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Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.133 Butane-2,3-diol 3.0 3900 Class I 1800 
07.097 3-(Hydroxymethyl)octan-2-one 15 1600 Class I 1800 
07.165 4-Hydroxy-4-methylpentan-2-one 0.085 1600 Class I 1800 
07.167 4-Hydroxyhexan-3-one 0.0012 1600 Class I 1800 
07.238 3-Hydroxy-2-octanone 0.0049 1600 Class I 1800 
07.071 Octane-4,5-dione 0.0012 1600 Class II 540 
07.152 3,3-Diethoxybutan-2-one 0.088 1600 Class II 540 
07.248 Octan-2,3-dione 0.37 1600 Class II 540 
07.260 1- or 3-Hydroxy-5-methyl-2- or 3-hexanone 2.3 1500 Class II 540 
06.134 Diacetyl-trimer 1.2 5400 Class II 540 
07.184 3-Methylnona-2,4-dione 0.12 1600 Class II 540 
07.168 2-Hydroxypiperitone 0.0012 1600 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances.  
On the basis of the reported annual production volumes in Europe (EFFA, 2003e; EFFA, 2003f; 
EFFA, 2004x; EFFA, 2007l; Flavour Industry, 2005a; Flavour Industry, 2005b) the estimated 
combined daily per capita intake as flavourings of the ten remaining candidate substances assigned to 
structural class I, II or III is 22 microgram. This combined intake does not exceed the thresholds of 
concern for substances belonging to structural class I of 1800 or II of 540 or III of 90 
microgram/person/day, respectively. 
The 12 candidate substances [FL-no: 02.133, 06.134, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 
07.184, 07.238, 07.248 and 07.260] are structurally related to 13 supporting substances, which all are 
alpha-diketones or precursors evaluated by the JEFCA at its 51st meeting. For 12 of these supporting 
substances European annual production volumes have been provided by Flavour Industry. The 12 
supporting substances are all assigned to structural class II. The total estimated combined daily intake 
of the candidate and supporting substances (in Europe) is approximately 4600 microgram/capita, 
which would exceed the threshold of concern for structural class II (540 microgram/person/day). 
However, based on the high capacity of enzymes in the metabolic pathways, it is anticipated that the 
combined intake of candidate substances (22 microgram/capita/day) and supporting substances (4600 
microgram/capita/day) would be metabolised efficiently and would not saturate these metabolic 
pathways. Further, based on the data available, two supporting substances (diacetyl [FL-no: 07.052] 
2200 microgram/capita/day and 3-hydroxybutan-2-one [FL-no: 07.051] 2300 microgram/capita/day) 
out of the total of 25 candidate and supporting substances provide 95 % of the contribution. These are 
present in the body as endogenous compounds (Kawano, 1959; Gabriel et al., 1972) and they would 
not be expected to give rise to perturbations outside the physiological range (JECFA, 1999a). 
Therefore, at the level of exposure, based on the MSDI approach, the total combined intake as 
flavouring substances of the candidate and supporting substances would not be expected to be of 
safety concern. 
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8. Toxicity 
8.1. Acute Toxicity 
Data are available for two candidate substances ([FL-no: 02.133 and 07.165]) and for pentan-2,4-dione 
and for six of the supporting substances [FL-no: 07.018, 07.051, 07.052, 07.060, 07.064 and 09.264] 
evaluated by JECFA (JECFA, 1999a).  
Oral LD50 values in rats and mice are in the range from 600 to 9000 mg/kg body weight (bw). 
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data on oral subacute toxicity are available for one candidate substance ([FL-no: 07.165]), for the 
structurally related pentan-2,4-dione and for three supporting substances [FL-no: 07.051, 07.052 and 
07.077] evaluated by the JECFA (JECFA, 1999a). There are no studies available on chronic toxicity 
and carcinogenicity for the candidate substances. No Observed Adverse Effect Levels (NOAELs) in 
the range of 10 - 100 mg/kg bw/day in rats (and rabbits) have been derived from subacute studies for 
one candidate substance [FL-no: 07.165] and for pentan-2,4-dione and in the range of 90-330 mg/kg 
bw/day from subchronic studies in rats for two supporting substances [FL-no: 07.051 and 07.052].  
Repeated dose toxicity data are summarised in Annex IV, Table IV.2.  
8.3. Developmental / Reproductive Toxicity Studies 
There are no data available for candidate substances. For supporting substances there is one 
developmental toxicity study available for diacetyl [FL-no: 07.052] in which no adverse effects were 
observed at the applied dose levels up to 1600 mg/kg bw/day in hamsters, mice and rats.  
Developmental/reproductive toxicity data summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
In vitro data are available for four candidate substances [FL-no: 02.133, 06.134, 07.165 and 07.184], 
for the structurally related pentan-2,4-dione and for five supporting substances [FL-no: 07.051, 
07.052, 07.060, 07.018 and 07.077].  
For one of the candidate substances, 4-hydroxy-4-methylpentan-2-one [FL-no: 07.165], in vitro 
studies have been reported with negative results obtained in bacterial gene mutation assays with and 
without metabolic activation as well as in a chromosomal aberration assay in rat liver cells in vitro. 
For a second candidate substance butane-2,3-diol [FL-no: 02.133], there is only one Ames test 
reported to be negative, but the validity of the study cannot be evaluated. No evidence of mutagenicity 
was reported in standard or modified Ames assays considered valid when 3-methyl-2,4-nonanedione 
[FL-no: 07.184] and diacetyl-trimer [FL-no: 06.134] were incubated with various strains of S. 
typhimurium or E. coli at concentrations up to 5000 μg/plate, with and without metabolic activation 
(Stien, 2005b; Sasaki, 2006). 
For pentan-2,4-dione, both in vitro and in vivo studies are available. In the various in vitro studies 
reported (reverse mutation assays (Ames Tests), microbial DNA repair tests and tests on primary DNA 
damage, gene mutation and chromosomal aberrations) negative results were observed in one Ames 
Test with five tester strains of S. typhimurium with and without metabolic activation. Positive results 
were found in two Ames Tests with S. typhimurium strain TA104 with or without metabolic 
activation. Positive results were also observed in the chromosomal aberrations test in the absence of 
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metabolic activation. For the three tests on microbial DNA repair both positive and negative results 
have been reported. However, they followed unusual study protocols and experimental details are 
insufficiently reported. Thus, the results are of limited validity. In two in vivo micronucleus studies 
using intraperitoneal dosing, which were performed in compliance with GLP and in accordance with 
OECD guideline 474 in mice significant increases in micronucleated polychromatic erythrocytes were 
observed in peripheral blood as well as in bone marrow. Test concentrations used were high and close 
to the LD50 determined in the same test system, however, there was no decrease in the ratio of 
PCE/NCE, on the contrary an increase was reported. The results were clearly positive in both studies 
which are considered as valid. The same test protocol was used in an in vivo micronucleus study in 
rats. However, test concentrations had to be reduced due to excessive mortality. Under these 
conditions, negative results were observed in the micronucleus test in rats. There were no significant 
changes in the proportion of PCE. Therefore, the validity of the results of this study is limited.  
Genotoxicity studies were also performed with five supporting substances: 
For 3-hydroxybutan-2-one (acetoin) [FL-no: 07.051] there is only one valid negative Ames test while 
data from other in vitro studies (results of which were reported to be negative) cannot be considered as 
valid. Diacetyl [FL-no: 07.052] was found able to induce gene mutations in S. typhimurium TA100 
and TA104. Diacetyl was reported to produce mutations in the TK +/- locus of L5178Y mouse 
lymphoma cells. However, the concentration required for a two-fold increase in mutations results in a 
62 % growth reduction, rendering this effect questionable (Whittaker et al., 2008). In an unpublished 
GLP study on in vivo micronucleus formation in B6C3F1 mice diacetyl was reported negative, 
however, since the PCE/NCE ratio was not reported it is not clear whether the test substance reached 
the target organ (NTP, 1994c). Hexan-3,4-dione [FL-no: 07.077] slightly induced gene mutations in 
bacteria. No genotoxic activity was observed in valid in vitro studies with pentan-2,3-dione [FL-no: 
07.060] and hexan-2,3-dione [FL-no: 07.018] (see Table IV.4.). 
Conclusion on genotoxicity: 
There are mutagenicity data on two candidate substances ([FL-no: 02.133, 06.134, 07.165 and 
07.184]) and for the structurally related pentan-2,4-dione in this flavouring group evaluation. 
4-Hydroxy-4-methylpentan-2-one [FL-no: 07.165] was not mutagenic in various in vitro studies in 
bacteria and yeast and did not induce chromosomal aberrations in rat liver cells. For butane-2,3-diol 
[FL-no: 02.133] negative results were reported in an in vitro gene mutation study, of which, however, 
the validity cannot be evaluated. No evidence of mutagenicity was reported in Ames assays considered 
valid when 3-methyl-2,4-nonanedione [FL-no: 07.184] and diacetyl-trimer [FL-no: 06.134] were 
incubated with various strains of S. typhimurium or E. coli.  
The structurally related pentan-2,4-dione is genotoxic in vitro and in vivo. In in vitro studies 
considered as valid, it induced chromosomal aberrations without metabolic activation and sister 
chromatid exchanges with and without metabolic activation while no gene mutations were observed in 
bacteria and mammalian cells. In vivo, pentan-2,4-dione induced micronuclei in mice peripheral blood 
and bone marrow. It should be noted that only pentan-2,4-dione exhibits the structural feature of a 
methylene group which is activated due to its position between two carbonyl groups. 
Mutagenicity data are available for five of the 13 supporting substances, giving mainly negative 
results. There is indication that diacetyl [FL-no: 07.052] has a weak genotoxic activity in vitro. 
However, diacetyl is reported to be endogenous in humans and is reported to be rapidly reduced to 
acetoin and further to butan-2,3-diol, for which there are no indication of mutagenicity. 
Overall, the genotoxicity data available on candidate and supporting substances do not preclude 
evaluation of the candidate substances in the present group using the Procedure. For 3-methyl-2,4-
nonadione [Fl-no: 07.184], which contains a structural 2,4-dione element similar to pentan-2,4-dione 
no in vivo genotoxicity data were available. 
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Genotoxicity data are summarised in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The present flavouring group includes 12 candidate substances; nine alpha-diketones or their 
corresponding alcohols or ketals [FL-no: 02.133, 06.134, 07.071, 07.152, 07.167, 07.168, 07.238, 
07.248 and 07.260], and three beta-diketones or their corresponding beta-hydroxyketones (of which 
one is a tertiary alcohol) [FL-no: 07.165, 07.097 and 07.184] all belonging to chemical groups 8 and 
10. 
One of the 12 candidate substances possesses four chiral centres [FL-no: 06.134] two possesses two 
chiral centres [FL-no: 02.133 and 07.168] and four substances possesses one chiral centre [FL-no: 
07.097, 07.167, 07.184 and 07.238]. One of the substances [FL-no: 07.260] is a mixture of four 
isomers. 
Five of the candidate substances are classified in structural class I, and six are classified in structural 
class II and one is classified in structural class III.  
Eight of the 12 candidate substances in the present group have been reported to occur naturally in a 
wide range of food items. 
According to the default MSDI approach, the 12 candidate substances have European daily per capita 
intakes ranging from 0.0012 to 15 microgram, which are below the thresholds of concern for structural 
class I, II and III (1800, 540 and 90 microgram/person/day, respectively). 
On the basis of the reported annual production in Europe (MSDI approach) the combined intakes of 
the candidate substances, assigned to structural class I, II or III, is 22 microgram. This combined 
intake does not exceed the threshold of concern for a substances belonging to structural class I of 1800 
or II of 540 or class III of 90 microgram/person/day, respectively. The supporting substances are all 
assigned to structural class II. The total combined estimated levels of intake of candidate and 
supporting substances is approximately 4600 microgram/capita, which would exceed the threshold of 
concern for structural class II (540 microgram/person/day). However, based on information on 
efficient metabolism and on presence in the body as endogenous compounds, there are no safety 
concerns from the combined intakes of the candidate and supporting substances. 
The candidate substance 3-methyl-2,4-nonadione [FL-no: 07.184] contains a structural 2,4-dione 
element similar to pentan-2,4-dione. The only genotoxicity data available for this substance was a 
valid unpublished GLP study in S. typhimurium and E. coli which were both negative. Similar 
negative result was obtained for pentan-2,4-dione in a valid GLP study in Salmonella, however, 
positive genotoxicity results were obtained in other studies both in vitro and in vivo. Due to this 
anticipated structural alert for genotoxicity (the 2,4-dione structure) the Procedure was not applied for 
3-methyl-2,4-nonadione [FL-no: 07.184] and accordingly additional data on genotoxicity are required. 
For the remaining candidate substances, genotoxicity data are only available for a limited number of 
substances, and the genotoxicity could not be assessed adequately. However, the genotoxicity data 
available on these 11 remaining candidate substances do not preclude evaluation using the Procedure. 
Ten of the 11 flavouring substances evaluated through the Procedure are expected to be metabolised to 
innocuous products. 
For the remaining candidate substance evaluated through the Procedure, diacetyl-trimer [FL-no: 
06.134], the data available do not allow to anticipate hydrolysis to innocuous products. No NOAEL 
exists for the substance or a structurally related substance to provide an adequate margin of safety 
under the conditions of intended use and accordingly additional data are required. 
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It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It is considered that on the basis of the default MSDI approach the ten of the 11 candidate substances 
evaluated through the Procedure [FL-no: 02.133, 07.071, 07.097, 07.152, 07.165, 07.167, 07.168, 
07.238, 07.248 and 07.260] would not give rise to safety concerns at the estimated levels of intake 
arising from their use as flavouring substances. 
When the estimated intakes were based on the mTAMDI they ranged from 1600 to 3900 
microgram/person/day for the five candidate substances from structural class I. For one of these 
candidate substances [FL-no: 02.133] the estimated intake is above the threshold of concern of 1800 
microgram/person/day for structural class I. For the six candidate substances, which are assigned to 
structural class II, the estimated intake based on the mTAMDI range from 1500 to 5400 microgram/ 
person/day, which is above the threshold of concern for structural class II of 540 
microgram/person/day. For the one candidate substance [FL-no: 07.168] from structural class III the 
mTAMDI value is 1600 microgram/person/day, which exceeds the threshold of concern for structural 
class III of 90 microgram/person/day. The four candidate substances [FL-no: 07.097, 07.165, 07.167, 
07.238], which have mTAMDI intake estimates below the threshold of concern for structural class I 
are also expected to be metabolised to innocuous products. 
Thus, for seven of the 11 candidate substances evaluated through the Procedure [FL-no: 02.133, 
06.134, 07.071, 07.152, 07.168, 07.248 and 07.260] the intakes, estimated on the basis of the 
mTAMDI exceed the threshold for the structural class, to which the flavouring substances have been 
assigned. Therefore, more reliable exposure data are required. On the basis of such additional data, the 
substances should be reconsidered along the steps of the Procedure. Following this procedure 
additional toxicological data might become necessary. 
In order to determine whether the conclusion for the candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. The stereoisomeric 
compositions have not been specified for three of the substances [FL-no: 06.134,  07.184 and 07.260]. 
One of the substances [FL-no: 07.260] is a mixture of four isomers (three positional isomers, where 
one of these can exists as two stereoisomers) and the composition of mixture is not specified. 
Furthermore, for [FL-no: 07.097] the minimum assay is too low, so information on secondary 
components of [FL-no: 07.097] is missing.  
Thus, the final evaluation of the materials of commerce cannot be performed for four substances [FL-
no: 06.134, 07.097, 07.184 and 07.260], pending further information. For the candidate substance 
diacetyl-trimer [FL-no: 06.134] additional metabolism/toxicity data are required, and for 3-methyl-
2,4-nonadione [FL-no: 07.184] data on genotoxicity are required before it can be evaluated through 
the Procedure. 
The remaining eight substances [FL-no: 02.133, 07.071, 07.152, 07.165, 07.167, 07.168, 07.238 and 
07.248] would present no safety concern at the levels of intake estimated on the basis of the MSDI 
approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 11, REVISION 2 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 11, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.133 
 
Butane-2,3-diol 
OH
OH  
10181 
513-85-9 
Liquid 
C4H10O2 
90.12 
Soluble 
1 ml in 1 ml 
181 
 
MS 
95 % 
1.432-1.438 
1.001-1.007 
 
Racemate (EFFA, 2010a).  
06.134 
 
Diacetyl-trimer   6) O
O
O
O
HO
O
 
4303 
 
18114-49-3 
Solid 
C12H18O6 
258.27 
Soluble 
Soluble 
 
90 
MS 
95 % 
n.a. 
n.a. 
 
Stereoisomeric composition 
not specified by CASrn in 
Register. Register name to 
be changed to: 1,1'-
(tetrahydro-6a-hydroxy-
2,3a,5-trimethylfuro[2,3-d]-
1,3-dioxole-2,5-diyl)bis-
ethanone. 
07.071 
 
Octane-4,5-dione 
O
O  
2141 
5455-24-3 
Liquid 
C8H14O2 
142.20 
Slightly soluble 
1 ml in 1 ml 
168 
 
MS 
95 % 
1.415-1.421 
0.907-0.913 
 
 
07.097 
1839 
3-(Hydroxymethyl)octan-2-one 
OH
O 3292 
11113 
59191-78-5 
Liquid 
C9H18O2 
158.24 
Slightly soluble 
1 ml in 1 ml 
80 (0.3 hPa) 
 
NMR 
92 % 
1.416-1.422 
0.874-0.878 
 
Racemate (EFFA, 2010a).  
Min. Assay value 92 %, 
secondary components to be 
specified. 
07.152 
 
3,3-Diethoxybutan-2-one 
O
O
O
 
 
51933-13-2 
Liquid 
C8H16O3 
160.21 
Slightly soluble 
1 ml in 1 ml 
164 
 
MS 
95 % 
1.400-1.406 
0.919-0.925 
 
 
07.165 
 
4-Hydroxy-4-methylpentan-2-one O
OH
 
 
123-42-2 
Liquid 
C6H12O2 
116.16 
Slightly soluble 
1 ml in 1 ml 
165 
 
MS 
95 % 
1.418-1.424 
0.929-0.935 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 11, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
07.167 
 
4-Hydroxyhexan-3-one O
OH
 
11108 
4984-85-4 
Liquid 
C6H12O2 
116.16 
Sparingly soluble 
1 ml in 1 ml 
167 
 
MS 
95 % 
1.422-1.428 
0.949-0.955 
 
Racemate (EFFA, 2010a).  
07.168 
 
2-Hydroxypiperitone 
OH
O
O
O
4143 
 
490-03-9 
Solid 
C10H16O2 
168.24 
Slightly soluble 
1 ml in 1 ml 
233 
82 
NMR MS 
98 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2010a).  
07.184 
 
3-Methylnona-2,4-dione   6) OO 4057 
 
113486-29-6 
Liquid 
C10H18O2 
170.25 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
52 (0.13 hPa) 
 
IR NMR MS 
97 % 
1.448-1.454 
0.923-0.927 
 
(R)- or (S)-enantiomer not 
specified by CASrn in 
Register. 
07.238 
 
3-Hydroxy-2-octanone O
OH
 
 
37160-77-3 
Liquid 
C8H16O2 
144.21 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
91 (13 hPa) 
 
MS 
95 % 
1.431-1.437 
0.927-0.933 
 
Racemate (EFFA, 2010a).  
07.248 
 
Octan-2,3-dione O
O
4060 
 
585-25-1 
Liquid 
C8H14O2 
142.2 
Soluble 
1 ml in 1 ml 
58 (1.3 hPa) 
 
IR NMR MS 
95 % 
1.419-1.424 
0.905-0.913 
 
 
07.260 
 
1- or 3-Hydroxy-5-methyl-2- or 3-
hexanone   6) 
O
OH
3-Hydroxy-5-methyl-2-hexanone shown
 
 
 
163038-04-8 
Liquid 
C7H14O2 
130.18 
Soluble 
Soluble 
171-173 
 
MS 
95 % 
0.921-0.933 
1.419-1.431 
 
Register name to be changed 
to 1-hydroxy-5-methyl-3-
hexanone and 3-hydroxy-5-
methyl-2-hexanone. 
Composition of 
stereoisomers and positional 
isomers not specified. 
CASrn in Register refers to 
the racemate of 3-hydroxy-
5-methyl-2-hexanone. 
1) Solubility in water, if not otherwise stated. 
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2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
 
Flavouring Group Evaluation 11, Revision 2
 
 
21 EFSA Journal 2011; 9(2):1170 
TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.133 
 
Butane-2,3-diol 
OH
OH 3.0 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.097 
1839 
3-(Hydroxymethyl)octan-2-one 
OH
O 15 
 
Class I 
A3: Intake below threshold 
4) 8)  
07.165 
 
4-Hydroxy-4-methylpentan-2-
one 
O
OH
0.085 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.167 
 
4-Hydroxyhexan-3-one O
OH
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.238 
 
3-Hydroxy-2-octanone O
OH
0.0049 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.071 
 
Octane-4,5-dione 
O
O 0.0012 
 
Class II 
A3: Intake below threshold 
4) 6)  
07.152 
 
3,3-Diethoxybutan-2-one 
O
O
O
0.088 
 
Class II 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
07.248 
 
Octan-2,3-dione O
O
0.37 
 
Class II 
A3: Intake below threshold 
4) 6)  
07.260 
 
1- or 3-Hydroxy-5-methyl-2- or 
3-hexanone 
O
OH
3-Hydroxy-5-methyl-2-hexanone shown
2.3 
 
Class II 
A3: Intake below threshold 
4) 7)  
06.134 
 
Diacetyl-trimer O
O
O
O
HO
O 1.2 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
07.184 
 
3-Methylnona-2,4-dione OO 0.12 
 
Class II 
No evaluation 
  a) 
07.168 
 
2-Hydroxypiperitone 
OH
O
O
O
0.0012 
 
Class III 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot.. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
a) Additional data on genotoxicity required 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE KETAL  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Ketal 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
- 3-Hydroxy-3-methyl-hept-2,5,6-
trione 
O
O
O
OH
Not in register Not in register Anticipated  hydrolysis products of 
diacetyl-trimer [FL-no: 06.134]. 
02.078 Ethanol 
41 OH  
Category 1 a) 
No safety concern b) 
 
 
 
No evaluation 
At the forty-sixth JECFA meeting (JECFA, 
1997a), the Committee concluded that 
ethanol posed no safety concern at its 
current level of intake when ethyl esters are 
used as flavouring agents. 
07.052 Diacetyl 
408 
O
O
 
No safety concern c) 
Category A d) 
 
Class II 
A3: Intake above threshold, A4: 
Endogenous 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (SCF, 1995). 
b) (JECFA, 1997a). 
c) (JECFA, 2000a). 
d) (CoE, 1992). 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
07.018 Hexan-2,3-dione 
O
O 2558 
152 
3848-24-6 
412 
JECFA specification (JECFA, 
2000d) 
8.5  
No safety concern a) 
Category A b) 
 
07.021 Undeca-2,3-dione 
O
O 3090 
155 
7493-59-6 
417 
JECFA specification (JECFA, 
2003b) 
0.0037  
No safety concern a) 
Category A b) 
 
07.051 3-Hydroxybutan-2-one O
OH
2008 
749 
513-86-0 
405 
JECFA specification (JECFA, 
1998b) 
2300  
No safety concern a) 
Category A b) 
JECFA evaluated 
acetoin (CASrn as in 
Register). (R)- or (S)-
enantiomer not specified 
by CASrn in Register. 
07.052 Diacetyl O
O
2370 
752 
431-03-8 
408 
JECFA specification (JECFA, 
1998b) 
2200  
No safety concern a) 
Category A b) 
 
07.060 Pentan-2,3-dione O
O
2841 
2039 
600-14-6 
410 
JECFA specification (JECFA, 
2003b) 
130  
No safety concern a) 
Category A b) 
 
07.063 4-Methylpentan-2,3-dione O
O
2730 
2043 
7493-58-5 
411 
JECFA specification (JECFA, 
2000d) 
0.3  
No safety concern a) 
Category A b) 
 
07.064 Heptan-2,3-dione O
O
2543 
2044 
96-04-8 
415 
JECFA specification (JECFA, 
1998b) 
0.97  
No safety concern a) 
Category A b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
07.065 5-Hydroxyoctan-4-one 
O
OH 2587 
2045 
496-77-5 
416 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
Deleted b) 
JECFA evaluated 5-
hydroxy-4-octanone 
(CASrn as in Register). 
CASrn in Register refers 
to the racemate. 
07.077 Hexan-3,4-dione 
O
O 3168 
2255 
4437-51-8 
413 
JECFA specification (JECFA, 
1998b) 
21  
No safety concern a) 
Category A b) 
 
07.093 5-Methylhexan-2,3-dione O
O
3190 
11148 
13706-86-0 
414 
JECFA specification (JECFA, 
2000d) 
1.1  
No safety concern a) 
 
 
07.125 3-Hydroxypentan-2-one O
OH  
3550 
11115 
3142-66-3 
409 
JECFA specification (JECFA, 
2003b) 
ND  
No safety concern a) 
 
JECFA evaluated 3-
hydroxy-2-pentanone 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by CASrn 
in Register. 
09.186 sec-Butan-3-onyl acetate 
O
O
O
 
3526 
608 
4906-24-5 
406 
JECFA specification (JECFA, 
2000d) 
0.024  
No safety concern a) 
Category A b) 
JECFA evaluated 2-
acetoxy-3-butanone 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by CASrn 
in Register. 
09.264 sec-Butan-3-onyl butyrate 
O
O
O  
3332 
10525 
84642-61-5 
407 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern a) 
 
JECFA evaluated butan-
3-one-2-yl butanoate 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by CASrn 
in Register. 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2000a). 
b) (CoE, 1992). 
ND)  No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated intakes of 
the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated; 
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.I Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
The “normal and maximum use levels” are provided by Industry (EFFA, 2003e; EFFA, 2003f; EFFA, 
2004x; EFFA, 2007a;  EFFA, 2007l; Flavour Industry, 2005a; Flavour Industry, 2005b) for all the candidate 
substances in the present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.11 (EFFA, 2003e; 
EFFA, 2003f; EFFA, 2004x; EFFA, 2007a;  EFFA, 2007l; Flavour Industry, 2005a; Flavour Industry, 2005b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.133 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
06.134 20 
100 
10 
50 
5 
10 
- 
- 
- 
- 
10 
50 
20 
50 
20 
50 
- 
- 
- 
- 
- 
- 
- 
- 
20 
100 
- 
- 
5 
10 
10 
20 
10 
50 
10 
30 
07.071 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.097 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.152 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.165 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.167 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.168 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.184 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.11 (EFFA, 2003e; 
EFFA, 2003f; EFFA, 2004x; EFFA, 2007a;  EFFA, 2007l; Flavour Industry, 2005a; Flavour Industry, 2005b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
07.238 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.248 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.260 3 
6 
- 
- 
3 
7 
3 
6 
3 
6 
3 
6 
- 
- 
3 
3 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
3 
6 
3 
6 
- 
- 
- 
- 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
The mTAMDI values (see Table II.2.3) are presented for all of the flavouring substances in the present 
flavouring group (EFFA, 2003e; EFFA, 2003f; EFFA, 2004x; EFFA, 2007l; Flavour Industry, 2005a; 
Flavour Industry, 2005b). The mTAMDI values are only given for highest reported normal use levels (see 
Table II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
02.133 Butane-2,3-diol 3900 Class I 1800 
07.097 3-(Hydroxymethyl)octan-2-one 1600 Class I 1800 
07.165 4-Hydroxy-4-methylpentan-2-one 1600 Class I 1800 
07.167 4-Hydroxyhexan-3-one 1600 Class I 1800 
07.238 3-Hydroxy-2-octanone 1600 Class I 1800 
07.071 Octane-4,5-dione 1600 Class II 540 
07.152 3,3-Diethoxybutan-2-one 1600 Class II 540 
07.248 Octan-2,3-dione 1600 Class II 540 
07.260 1- or 3-Hydroxy-5-methyl-2- or 3-hexanone 1500 Class II 540 
06.134 Diacetyl-trimer 5400 Class II 540 
07.184 3-Methylnona-2,4-dione 1600 Class II 540 
07.168 2-Hydroxypiperitone 1600 Class III 90 
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ANNEX III: METABOLISM 
III.1. Absorption, Distribution and Elimination 
The candidate substances and supporting substances which are aliphatic acyclic alpha-diketones participate 
in a keto-enol equilibrium with the corresponding ketoenol (see Figure III.1). The keto form predominates 
(Gordon & Ford, 1972). 
In rats and mice, orally administered acetoin (3-hydroxybutan-2-one [FL-no: 07.051]) is rapidly absorbed 
from the gastrointestinal tract (Gabriel et al., 1972). Upon injection of acetoin-2,3-14C to albino rats, 14CO2 
appears in the expired air. The average 12-20 hours 14CO2 production from acetoin-2,3-14C was found to be 
15 % after intraperitoneal (i.p.) administration (12 hours) and 47.7 % after intracardial administration (20 
hours) (Gabriel et al., 1972). 
CO2 + OH
O
O
CO2 + H2O
O
O
O
OH
OH
OH
OH
OgluO
Oglu
glucuronosyl
transferase
glucuronosyl
transferase
alpha-hydroxyketonealpha-diketonic 
form
reduction reduction
O
OH
alpha-ketoenolic form
Oglu = O-glucuronic acid
2,3-diol
 
Figure III.1 Keto-enol equilibrium and metabolism of aliphatic acyclic and alicyclic alpha-dicarbonyls 
III.2. Biotransformation 
III.2.1. Hydrolysis 
Ketals are anticipated to be readily hydrolysed after ingestion under the acid conditions in the stomach to 
their corresponding alcohol and ketone prior to absorption. 
In vitro studies conducted on diacetyl-trimer [FL-no: 06.134] (1,1’-(tetrahydro-6a-hydroxy-2,3a,5-
trimethylfuro[2,3-d]-1,3-dioxole-2,5-diyl)bis-ethanone) in simulated gastric juice showed 100 % 
disappearance of diacetyl-trimer within 12 hours. Similar studies conducted in artificial saliva showed 75 % 
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disappearance of diacetyl-trimer at pH 9 within 45 minutes (Guentert, 2004). However, no data on the 
identities of the hydrolysis products formed were provided. 
In general, esters are hydrolysed to their corresponding alcohol and carboxylic acid. Classes of enzymes 
recognized as carboxylesterases or esterases, the most important of which are the B-esterases, catalyse 
hydrolysis. Acetyl esters are the preferred substrates of C-esterases (Heymann, 1980). In mammals these 
enzymes occur in most tissues throughout the body (Anders, 1989; Heymann, 1980) but predominate in 
hepatocytes (Heymann, 1980). As an example, it is expected that the supporting chemicals, 2-acetoxy-3-
butanone and butanon-3-one-2-yl butanoate, are metabolised in humans to acetic acid and butanoic acid, 
respectively, and acetoin. 
III.2.2. Metabolism of Aliphatic Acyclic Diketones 
The metabolic fate of acyclic aliphatic diketones depends primarily on the position of the carbonyl function 
and the chain length. Aliphatic acyclic diketones and alpha–hydroxyketones, which contain a carbonyl 
function at the 2-position (i.e. a methyl ketone) may undergo alpha–hydroxylation and subsequent oxidation 
of the terminal methyl group to eventually yield corresponding ketocarboxylic acids. The ketoacids are 
intermediary metabolites (e.g. alpha-ketoacids), which may undergo oxidative decarboxylation to yield 
carbon dioxide and an aliphatic carboxylic acid. The acid may be completely metabolised in the fatty acid 
pathway and citric acid cycle (see Figure III.1). Beta-keto-acids and derivatives readily undergo 
decarboxylation. Along with alpha-keto- and alpha-hydroxyacids, they yield breakdown products, which are 
incorporated into normal biochemical pathways (EFSA, 2005b). 
Alternately, the methyl-substituted diketones may be successively reduced to the corresponding 
hydroxyketones and diols, which are excreted in the urine as glucuronic acid conjugates. This pathway is 
favoured at elevated in vivo concentrations, especially for longer chain length ketones. If the carbonyl 
function is located elsewhere on the chain, reduction is the predominant detoxification pathway.  
Alpha-Hydroxyketones or their diol metabolites may be excreted as glucuronic acid conjugates (JECFA, 
1999a). 
Acetoin is metabolised primarily via oxidation at low concentrations in vivo and by reduction to 2,3-
butanediol (butane-2,3-diol) at high concentrations. It is estimated that the rat liver is capable of oxidising 86 
microgram (1 micromole) acetoin/g liver per day (Gabriel et al., 1972). 
Oxidation of the terminal methyl group may form an alpha-ketoacid, which undergoes cleavage to yield CO2 
and a carboxylic acid fragment. 
A total dose of 78 g of acetoin was administered to a dog over a two-month period. The doses were given 
orally in a 3 to 4 percent solution and subcutaneously in a 20 percent solution. 
Urine was collected under toluene from the beginning of the dosing period through 40 hours after the last 
treatment. Butane-2,3-diol was identified as the major urinary excretion product, ranging from 5 to 25 
percent of the dose. The remainder of the dose was completely metabolised (Westerfeld & Berg, 1943). 
In liver preparations obtained from rats and rabbits, greater than 95 % of the radioactivity of 2,3-14C-acetoin 
was detected as a mixture of stereoisomers of butane-2,3-diol (Gabriel et al., 1971). Although reductions of 
diacetyl and acetoin have been observed in animals in vivo and in animal tissue preparation in vitro at high 
concentrations, it appears that oxidation of diacetyl is a major endogenous metabolic pathway. 
Reduction of ketones is mediated by alcohol dehydrogenase and NADPH dependent cytosolic carbonyl 
reductases (Bosron & Li, 1980). Reduction of acetoin and diacetyl is catalysed by the substrate-specific 
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enzymes diacetyl reductase and acetoin reductase, respectively. In rat liver mince, diacetyl, acetoin and 
butane-2,3-diol are interconvertible (Gabriel et al., 1972). 
In male Wistar albino rats, a single oral dose of 5 mmol diacetyl/kg bw (430 mg diacetyl/kg bw) was 
metabolised by reduction to acetoin, which was present in high concentrations of major organs one hour after 
dosing. The subsequent reduction product, butane-2,3-diol, was detected in the liver, kidney and brain. Only 
10 minutes incubation time was required to convert 10 nmol (9 x 10-4 mg) diacetyl to 3.7 nmol (3 x 10-4 mg) 
acetoin and 6.3 nmol (6 x 10-4 mg) butane-2,3-diol in rat liver homogenate (Otsuka et al., 1996). The organ-
specific reductase activity was greatest in the liver and least in the brain (Otsuka et al., 1996). 
Diacetyl and acetoin are reported to be endogenously formed in cats when pyruvate is converted to diacetyl 
and acetoin by pyruvate decarboxylase (Gabriel et al., 1972). Mean fasting blood acetoin levels of 
approximately 100 microgram acetoin/100 ml blood have been reported (Dawson & Hullin, 1954). Pyruvate 
also forms diacetyl in vitro in rat liver preparations (Järnefelt, 1955) and in microorganisms (Juni & Heym, 
1956). 
Diacetyl, acetoin and butane-2,3-diol are also reported to be endogenous in humans at levels of 0.25 – 0.75 
microM, 2.2 microM and 5 -10 microM, respectively, in plasma. Plasma levels of diacetyl and acetoin, 
precursors of butane-2,3-diol were not affected by ethanol consumption, whereas plasma levels of butane-
2,3-diol were elevated in individuals defective in aldehyde dehydrogenase (Otsuka et al., 1999) showing that 
acetoin is rapidly reduced to butan-2,3-diol in humans. 
III.3. Studies on Candidate Substances 
Butane-2,3-diol [FL-no: 02.133]: 
Diacetyl, acetoin and butane 2,3-diol have been reported to be endogeous in humans. Higher levels of 
butane-2,3-diol, but not of diacetyl and acetoin were found in blood and urine of individuals defective in 
aldehyde dehydrogenase compared to normal individuals. This suggest that acetaldehyde formed from 
ethanol is converted to diacetyl, acetoin and eventually to butane-2,3-diol (Otsuka et al., 1999). The 
metabolic interrelationship of these chemicals is discussed above. Butane-2,3-diol may be an intermediate in 
the mammalian metabolism of acetaldehyde in vitro, and butane-2,3-diol and its oxidation metabolite, 
acetoin, have been reported as intermediates in the mammalian metabolism of pyruvate in vitro (Veech et al., 
1987; Montgomery et al., 1993). 
Butane-2,3-diol, 2-butanol and 3-hydroxy-2-butanone were identified as metabolites in the serum of guinea 
pigs injected i.p. with methyl ethyl ketone. 3-Hydroxy-2-butanone forms by alpha-hydroxylation of methyl 
ethyl ketone that subsequently forms butane-2,3-diol by reduction of the ketone function. The half-life of 
methyl ethyl ketone in serum was 270 minutes, and the clearance time of butane-2,3-diol was 16 hours 
(DiVincenzo et al., 1976). A proposed pathway of butane-2,3-diol elimination is as 2,3-butanediol beta-
glucuronide after coupling with UDP-glucuronyltransferase (Otsuka et al., 1999). 
4-Hydroxy-4-methylpentan-2-one [FL-no: 07.165]: 
4-Hydroxy-4-methylpentan-2-one and 4-methyl-2-pentanol were detected in serum after i.p. injection of 4-
methyl-2-pentanone to guinea pigs. 4-Hydroxy-4-methylpentan-2-one was the principal metabolite and was 
cleared in 16 hours. The concentration of 4-methyl-2-pentanol was too low for quantification. 4-Methyl-2-
pentanone is metabolised by oxidation at the omega-1 carbon atom to form the hydroxylated ketone, 4-
hydroxy-4-methylpentan-2-one, and to a lesser extent by reduction of the carbonyl group to form the 
secondary alcohol, 4-methyl-2-pentanol (DiVincenzo et al., 1976). 
Pentan-2,4-dione: 
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Pentan-2,4-dione was investigated for its comparative pharmacokinetics in male F344 rats (4/1 group) by 
single intravenous (i.v.) injection of 4.3, 43, 148.5 and 430 mg/kg bw, or a 6-hour nose only inhalation 
exposure to 14C-pentan-2,4-dione. Only the i.v. part of the study is reported here. The plasma concentration 
of 14C-pentan-2,4-dione derived radioactivity declined in a biexponential fashion. The 14C plasma 
concentration-time curves and derived pharmacokinetic parameters indicated that dose-linear kinetics 
occurred in the i.v. dose range of 4.3 to 148.5 mg/kg, but not at 430 mg/kg. Metabolism of pentan-2,4-dione 
was rapid in that the concentration of unmetabolised pentan-2,4-dione declined steadily to undetectable 
levels after eight hours. 14C-pentan-2,4-dione derived radioactivity was eliminated mainly as exhaled 14CO2 
and in the urine. In the 48-hour samples for the 4.3, 43 and 148.5 mg/kg doses, 14CO2 elimination was 
constant at 36.8, 38.8 and 42.3 %, and greater than the urinary 14C excretion of 17.9, 14.3 and 29.6 %, 
respectively. However, at the 430 mg/kg i.v. dose there was a reversal of the excretion pattern, with the urine 
14C excretion (54.7 %) becoming greater than the exhaled 14CO2 (27.3 %). Free parent compound and seven 
metabolites were detected in the 12-hour urine samples. In the 24-48-hour urine samples only one metabolite 
was detectable in small amounts (Frantz et al., 1998). At lower dose levels oxidation predominates, whereas 
at the high dose urinary hydroxylated metabolites formed by hydroxylation and ketone reduction 
predominate. These mechanisms are similar to those observed for diacetyl.  
III.4. Conclusions on Metabolism 
It is anticipated that humans will metabolise aliphatic acyclic methyl ketones principally by oxidation of the 
terminal methyl group at low levels of exposure. At higher levels, reduction to the diol and subsequent 
conjugation with glucuronic acid is a competing detoxification pathway. Other aliphatic acyclic diketones 
and hydroxyketones are reduced, conjugated with glucuronic acid and excreted. The ketals in the present 
FGE are anticipated to be hydrolysed to the corresponding alcohols and ketones. For one substance, diacetyl-
trimer [FL-no: 06.134], the metabolism products can only partially be predicted. 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for two candidate substances of the present flavouring group evaluation from chemical groups 8 and 10, for six 
supporting substances evaluated by the JECFA at the 51th meeting and for one structurally related compound (pentan-2,4-dione). The supporting substances 
are listed in brackets. 
Table IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Acetoin [07.051]) Rat  NR  Oral  >5000  (Moreno, 1977d)  
Butane-2,3-diol [02.133]  Mouse  NR  Oral  9000  (Kopf et al., 1950)  
(Butan-3-one-2-yl butanoate [09.264]) Mouse  NR  Oral  >8000  (Pellmont, 1969a)  
 Rat  NR  Oral  >8000  (Pellmont, 1969a)   
(Diacetyl [07.052]) Rat  M, F  Gavage  M: 3400;  
F: 3000 
(Colley et al., 1969)  
 Rat  NR  Gavage  1580  (Jenner et al., 1964)  
 Guinea pig NR  Gavage  990  (Jenner et al., 1964)   
4-Hydroxy-4-methylpentan-2-one [07.165] Rat  M  Gavage  4920 (Myers et al., 1977a)  
 Rat  M  Oral  4000 (Smyth, 1946a)  
(2,3-Pentanedione [07.060]) Rat  NR  Oral  3000  (Moreno, 1977d)  
[Pentan-2,4-dione] Rat  M  Oral  1000 (Smyth, 1941)  
 Rat  M, F  Gavage  M: 780; 
F: 590  
(Ballantyne et al., 1986) 
(Myers et al., 1985)  
 
 Rat  M  Oral  800  (Eastman Kodak Co., 1992a)  
 Mouse  M  Oral  951  (Eastman Kodak Co., 1992a)  
(2,3-Hexanedione [07.018]) Rat  NR  Oral  >5000  (Moreno, 1977d)  
(2,3-Heptanedione [07.064]) Rat NR Oral >5000 (Moreno, 1979a)  
NR: Not reported 
M= Male; F= Female 
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Subacute / subchronic / chronic / Carcinogenic toxicity data are available for one candidate substance of the present flavouring group evaluation from 
chemical groups 8 and 10, for three supporting substances evaluated by the JECFA at the 51th meeting and for one structurally related compound (pentan-2,4-
dione). The supporting substances are listed in brackets. 
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg/day) 
Reference Comments 
(Acetoin [07.051])  Rat; M, F 
30 
Drinking 
water 
0, 85, 330, 1345 mg/kg 
bw/d 
90 Days  330  (Gaunt et al., 1972b) Non-GLP study of good quality carried out as part 
of the BIBRA safety evaluation programme; 
published in a peer reviewed journal. 
(Diacetyl [07.052])  Rat; M, F 
30 
Gavage  0, 10, 30, 90, 540 mg/kg 
bw/d 
90 Days  90  (Colley et al., 1969) Non-GLP study of good quality carried out as part 
of the BIBRA safety evaluation programme; 
published in a peer reviewed journal. 
4-Hydroxy-4-methylpentan-2-one 
[07.165] 
Rat;  NR 
10 
Drinking 
water 
0, 10, 40, 130 mg/kg bw/d 30 Days  10  (Smyth, 1946b) Unpublished non-GLP study of poor quality with 
respect to study protocol. No histopathological 
examination of high dose and control group. No 
details available for method and results. 
[Pentan-2,4-dione] Rat; M  
5 
Gavage  0, 100, 500, 1000 mg/kg 
bw/d 
1-15 Days1  100  (Eastman Kodak Co., 1992a) Non-GLP study of 1979 in unpublished summary 
report. No details available for method and results. 
Quality of study limited with respect to study 
design. Results of the study have been published in 
Neurotoxicity of Industrial and Commercial 
Chemicals, Vol. 2, I.L. O’Donoghue, Editor, CRC 
Press, Boca Raton, Florida. p.77 (1985). 
 Rat; M  
5 
Gavage  0, 100 mg/kg bw/d 14 Days2  1003  (Eastman Kodak Co., 1992a) 
 Rat; M  
5 
Gavage  0, 200 to 500 mg/kg bw/d 126 Days4  <2005  (Eastman Kodak Co., 1992a) 
 Rabbit; M 
2 
Gavage  0, 250, 500, 1000 mg/kg 
bw/d 
14 Days2  2506  (Eastman Kodak Co., 1992a) 
(3,4-Hexanedione [07.077]) Rat; M, F 
10-16 
Diet  0, 17 mg/kg bw/d 90 Days  173  (Posternak et al., 1969) Summary of an unpublished non-GLP study (on 42 
flavouring substances carried out in 1962-1967) 
prepared by BIBRA and published in a peer-
reviewed journal. 
M = Male; F = Female; NR= not reported.  
1 Animals dosed daily, between 1 and 11 times.  
2 Animals dosed ten times in fourteen days.  
3 The study was performed at a single dose level or multiple dose levels that produced no adverse effects. 
4 Animals dosed twice per day over a 126 day period at doses ranging from 100 to 250 mg/kg/day; animals that died or were killed during the study due to poor condition were replaced.  
5 NOAEL for the central nervous system was determined to be <200 mg/kg/day.  The NOAEL for thymus toxicity was determined to be 200 mg/kg/day.  
6 One rabbit (50% of the group population) died due to possible aspiration of the test substance.  
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No developmental and reproductive toxicity data are available for candidate substances of the present flavouring group evaluation from chemical groups 8 and 
10. Developmental and reproductive toxicity data are available for one supporting substance evaluated at the 51st JECFA meeting. Supporting substance is 
listed in brackets. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no] Study type 
Duration 
Species/Sex 
No/Group 
Route Dose levels 
mg/kg bw/day 
NOAEL (mg/kg/day), 
Including information of 
possible maternel toxicity 
Reference Comments 
(Diacetyl [07.052]) Developmental toxicity: 
Gestation days 6-10 
Hamster; F 
21-25 
Gavage  0, 16, 74.3, 345, 1600 mg/kg 
bw/d 
1600 (maternal)1, 3
1600 (foetal)2, 3 
(FDA, 1973) Unpublished non-GLP study of 
limited quality with respect to 
possible developmental effects 
Developmental toxicity: 
Gestation days 6-15 
Mouse; F 
21-24 
Gavage  0, 16, 74.3, 345, 1600 mg/kg 
bw/d 
1600 (maternal)1, 3
1600 (foetal)2, 3 
(FDA, 1973) Unpublished non-GLP study of 
limited quality with respect to 
possible developmental effects 
Developmental toxicity: 
Gestation days 6-15 
Rat; F 
21-23  
Gavage  0, 16, 74.3, 345, 1600 mg/kg 
bw/d 
1600 (maternal)1, 3
1600 (foetal)2, 3 
(FDA, 1973) Unpublished non-GLP study of 
limited quality with respect to 
possible developmental effects 
M = Male; F = Female.  
1 Based on observations of maternal survival, body weight and reproductive parameters.  
2 Based on observations of foetal survival and microscopic examination of foetal external, skeletal and soft tissues.  
3 The study was performed at a single dose level or multiple dose levels that produced no adverse effects and, therefore, a NOAEL was not determined. The NOAEL is probably higher than the reported dose level that produced no adverse effects.  
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In vitro mutagenicity/genotoxicity data are available for four candidate substances of the present flavouring group evaluation from chemical groups 8 and 10, 
for five supporting substances evaluated by the JECFA at the 51th meeting and for one structurally related compound (pentan-2,4-dione). Supporting 
substances are listed in brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no] Test System Test Object  Concentration Result  Reference  Comments 
(Acetoin [07.051]) Ames Test  S. typhimurium TA100 up to 4500 µg/plate  Negative1  (Garst et al., 1983) Non-GLP study. Outcome of the study is only 
summarised with limited experimental details and no 
test results reported. Validity of the study cannot be 
evaluated. 
Ames Test  S. typhimurium TA100 390 µg/plate  Negative2  (Kim et al., 1987b) Non-GLP study with limited information given on study 
protocol and results. Validity of the study cannot be 
evaluated. 
Ames Test  S. typhimurium TA98, TA100, TA102 0.44 – 44000 µg/plate Negative3  (Aeschbacher et al., 
1989) 
Good quality, non-GLP study. 
Ames Test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538; E. coli WP2 uvrA 
1 – 5000 µg/plate Negative2 (Iwata et al., 1984) Published study in Japanese. Results (i.e. average 
number of revertant colonies per plate from three plates 
for each test concentration, including positive and 
negative controls) are given in table. Only tested 
without metabolic activation. Validity of the study 
cannot be evaluated. 
Butane-2,3-diol [02.133] Ames Test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538; E. coli WP2 uvrA 
1 – 5000 µg/plate Negative2  (Iwata et al., 1984) Published study in Japanese. Results (i.e. average 
number of revertant colonies per plate from three plates 
for each test concentration, including positive and 
negative controls) are given in table. Only tested 
without metabolic activation. Validity of the study 
cannot be evaluated. 
(Diacetyl [07.052]) Ames Test  S. typhimurium TA100 90 µg/plate  Negative3 (Kim et al., 1987b) Non-GLP study with limited information given on study 
protocol and results. Validity of the study cannot be 
evaluated. 
Modified Ames Test S. typhimurium TA98, TA100, TA104;  
E. coli WP2 uvrA/pKM101 
NR  Positive1 (Kato et al., 1989) Only poorly  reported abstract. Validity of the study 
cannot be evaluated.  
Modified Ames Test S. typhimurium TA104 530 µg/plate   Positive   (Marnett et al., 1985a) Published non-GLP study assessing the sensitivity of the 
new base substitution strains TA102 and TA104 to the 
mutagenic effects of carbonyls. Metabolic activation not 
reported. Due to the limited details reported on 
experimental design and results the validity of the study 
cannot be evaluated 
Ames Test  S. typhimurium TA104 5 – 500 µg/plate4 Positive1 
Negative2 
(Shane et al., 1988) Poorly reported non-GLP study of limited validity. 
Results are difficult to interpretate. 
Ames Test  S. typhimurium TA100, TA102 5 – 500 µg/plate4 Negative3  (Shane et al., 1988) Poorly reported non-GLP study of limited validity. 
Results are difficult to interpretate. 
Ames Test  S. typhimurium TA100 152 – 950 µg/plate Positive2  (Dorado et al., 1992) Published non-GLP study of good quality. The number 
of revertants at the highest dose duplicated that of 
spontanous revertants. The effect was dose-related. 
Ames Test  S. typhimurium TA100 Approx. 400-600 µg/plate Positive3  (Bjeldanes & Chew, 
1979) 
Published non-GLP study. Due to the limited details 
reported on experimental design and results the validity 
of the study cannot be evaluated. 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no] Test System Test Object  Concentration Result  Reference  Comments 
Ames Test  S. typhimurium TA98 10 – 10000 µg/plate Negative  (Bjeldanes & Chew, 
1979) 
Published non-GLP study. Due to the limited details 
reported on experimental design and results the validity 
of the study cannot be evaluated. 
Ames Test  S. typhimurium TA102 0.17 – 17200 µg/plate Positive3,  (Aeschbacher et al., 
1989) 
Good quality, non-GLP study. The number of revertants 
at the highest dose duplicated that of spontanous 
revertants. 
Ames Test  S. typhimurium TA98, TA100 0.17 – 17200 µg/plate Negative3 (Aeschbacher et al., 
1989) 
Good quality, non-GLP study. 
Modified Ames Test S. typhimurium TA100 1.8 and 4 mM 4 (107 and 238 
μg/pl)  
Positive2  (Suwa et al., 1982) Published non-GLP study with limited details reported 
on experimental design and results. The validity of the 
study is considered limited. 
Ames Test  S. typhimurium TA98, TA100, TA1535, 
TA1537,TA 1538; E. coli WP2 uvrA  
1 – 5000 µg/plate Negative2  (Iwata et al., 1984) Published study in Japanese. Results (i.e. average 
number of revertant colonies per plate from three plates 
for each test concentration, including positive and 
negative controls) are given in table. Only tested 
without metabolic activation. Validity of the study 
cannot be evaluated. 
Ames Suspension Test S. typhimurium TA1535, TA1537, 
TA1538 
1%  Negative3  (FDA, 1974) (not evaluated). 
Mutation  S. cerevisiae  NR  Negative3  (FDA, 1974) (not evaluated). 
Chromosomal 
Malsegregation Assay5 
S. cerevisiae D61.M 148 – 393 µg/ml Negative  (Zimmermann & Mohr, 
1992) 
Published non-GLP study. Study is considered valid. 
Forward Mutation  Mouse lymphoma L5178Y TK+/- cells  100 – 250 µg/ml  Positive (Whittaker et al., 2008) Published non-GLP study. The result was positive. 
However, the concentration required for a two-fold 
increase in mutations result in a 62% growth reduction, 
rendering this effect questionable.  
4-Hydroxy-4-methylpentan-2-one 
[07.165] 
Ames Test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538; 
100 – 10000 µg/plate Negative3  (San & Klug, 1993) Plate incorporation assay. Non-published GLP-study. 
Ames Test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538; E. coli  WP2, WP2 
uvrA 
Up to 4000 µg/plate Negative3  (Brooks et al., 1988) Plate incorporation assay. Published study summarising 
an extended industry report. Study is considered valid. 
Mitotic Gene Conversion 
Assay 
S. cerevisiae  10-5000 µg/ml  Negative3  (Brooks et al., 1988) Published study summarising an extended industry 
report. Study is considered valid. 
Chromosome Aberrations Rat liver epithelial type- cell line RL4 750, 1500, 2000, 3000, 4000 
µg/ml  
Negative  (Brooks et al., 1988) Published study summarising an extended industry 
report. Study is considered valid. 
(2,3-Pentanedione [07.060]) Ames Test  S. typhimurium TA100 105 µg/plate  Negative2  (Kim et al., 1987b) Non-GLP study with limited information given on study 
protocol and results. Validity of the study cannot be 
evaluated. 
Ames Test  S. typhimurium TA98, TA100, TA102 0.9 – 90000 µg/plate Negative3  (Aeschbacher et al., 
1989) 
Good quality, non-GLP study 
[Pentan-2,4-dione] Ames Test  S. typhimurium TA98, TA100, TA1535, 
1537, 1538; 
300 – 30000 µg/plate Negative3, 6  (Guzzie & Morabit, 
1985) 
Valid unpublished GLP-study carried out according to 
US EPA test guidelines. 
Ames Test  S. typhimurium TA92, TA98, TA100, 
TA104 
1.9 – 48 µmol/plate 
(190 –4805 µg/plate)7 
Negative
Positive 8 
(Gava et al., 1989) No data on cytotoxicity reported. Metabolic activation 
not reported. Due to the limited experimental details 
reported the validity of the study cannot be evaluated.  
Modified Ames Test S. typhimurium TA98, TA100, TA104;  
E. coli WP2 uvrA/pKM 101 
NR  Negative3   
Positive9 
Positive10 
(Kato et al., 1989) Only abstract reported. Validity of the study cannot be 
evaluated. 
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no] Test System Test Object  Concentration Result  Reference  Comments 
Umu Test  (DNA repair test) S. typhimurium TA1535/ pSK1002 196, 410, 1235 µg/ml Positive3, 11,12  (Ono et al., 1991) Published non-GLP study. Unusual study design. Due to 
the limited experimental details and results reported the 
validity of the study cannot be evaluated. Relevance of 
results are questioned. 
Rec-Assay (DNA repair test) B. subtilis H17 (Rec+), M45 (Rec –) CR50 Rec+ =209 μg/ml,  
CR50Rec– = 195 μg/ml13,2 
CR50 Rec+ =235 μg/ml,  
CR50Rec– = 173 μg/ml13,1 
Negative2
Very weakly 
positive1 
(Matsui et al., 1989) Insufficient report of study design and experimental 
details. Detailed results not reported. Validity of the 
study cannot be evaluated. 
Mitotic aneuploidy (DNA 
repair test) 
S. cerevisiae D61.M 0.74 – 1.96 % (7400 – 
19600µg/ml) 
Negative2  (Zimmermann et al., 
1985a) 
Published non-GLP study. Study is considered valid. 
Sister Chromatid Exchange Chinese Hamster Ovary Cells ~0.01 – 1.0 µmol/ml 
(~1 – 100µg/ml)14 
Positive  (Gava et al., 1989) Published non-GLP study. Due to the limited 
experimental details and the incomplete cytotoxicity 
data reported the validity of the study cannot be 
evaluated. 
 Sister Chromatid Exchange Chinese Hamster Ovary Cells 20, 30, 100 µg/ml  
30, 100, 300 µg/ml 
Positive2, 19  
Positive1, 19 
(Slesinski, 1986) Unpublished GLP study. Study is considered valid. 
HGPRT Mutation Assay Chinese Hamster Ovary Cells 10, 50, 100, 500, 1000 µg/ml 
 
Negative2, 15 
Negative1, 15 
(Slesinski, 1986) Cytotoxic effects at 1 mg/ml. Unpublished GLP study. 
Study is considered valid. 
Chromosomal Aberrations Chinese Hamster Ovary Cells 40 – 120 µg/ml (80, 100, 120 
µg/ml) 
60 – 140 µg/ml (100, 120, 
140 µg/ml) 
Positive2,16, 20 
Negative1,16 
(Guzzie & Morabit, 
1986) 
Three highest conentrations analysed. Mitotic cell 
division not excessively reduced at conentrations used 
(i.e. not cytotoxic). Effects observed were chromatid 
breaks. Good quality unpublished GLP study. 
(2,3-Hexanedione [07.018]) Chromosomal 
Malsegregation Assay17 
S. cerevisiae D61.M 372 – 833 µg/ml Negative18  (Zimmermann & Mohr, 
1992) 
Published non-GLP study. Study is considered valid. 
(3,4-Hexanedione [07.077]) Ames Test  S. typhimurium TA100 228 – 4900 µg/plate Very weakly 
positive2 
(Dorado et al., 1992) Published non-GLP study of good quality. 
3-Methylnona-2,4-dione [07.184] Revere mutation S. typhimurium TA100, TA1535, TA98, 
TA1537 
39, 78, 156, 313, 625 and 
1250 μg/plate 
 
Negative (Sasaki, 2006) Un-published GLP study. Study considered valid. 
Revere mutation E. Coli WP2uvrA 39, 78, 156, 313, 625 and 
1250 μg/plate 
 
Negative (Sasaki, 2006) Un-published GLP study. Study considered valid. 
Diacetyl-trimer [06.134] Revere mutation S. typhimurium TA98, TA100, TA102, 
TA1535, TA1537 
100, 316, 1000, 3160 or 5000 
μg/plate 
 
10, 31.6, 100, 316 or 1000 
μg/plate 
Negative3, 21, 
 
 
Negative22 
(Stien, 2005b) Un-published GLP study. Study considered valid. 
NR = Not reported.  
CR50 = 50 % survival concentrations for the B. subtilis strains. 
1 With metabolic activation.  
2 Without metabolic activation.  
3 With and without metabolic activation.  
4 Estimated from graphical data.  
5 Pure chemical at 28°C, starting titer 14.6 x 106 cells/ml; and pure chemical, cold shock, starting titer 9.1 x 106 cells/ml.  
6 Test substance was cytotoxic at 30000 µg/plate.  
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7 Calculated based on molecular weight = 100.12.  
8 Test substance was inactive towards TA92, TA98 and TA100 strains; however, it was mutagenic towards the TA104 strain. 
9 TA104 was positive in the absence of metabolic activation (specific activity = 2.25 revertants/µg); TA92, TA98 and TA100 were negative. 
10 WP2 uvrA/pKM 101 was positive in the presence of metabolic activation (specific activity = 7.73 revertants/μ g) and negative in the absence of metabolic activation.  
11 The highest concentration was only used in a 2-hour test (short term reaction) for which weakly positive result were reporteds.  
12 At 410 µg/ml a strongly positive results was reported after 24 hrs (long term reaction) with S9 metabolic activation, negative results were reported at 410 μg/ml after 2, 4 and 6 hrs with S9 metabolic activation and at 196 µg/ml after 2, 4 and 6 hrs 
and 20 hrs in the absence of S9 metabolic activation . 
13 The concentrations indicated are those of the test substance in the interaction period.  
14 Calculated based on molecular weight = 100.12.  
15 Cytotoxicity was observed, with and without S9 metabolic activation, at the 1.0 mg/ml dose level.  
16 Test substance was highly clastogenic in the absence of metabolic activation; however, in the presence of rat-liver S9 metabolic activation it was not clastogenic.  
17 Pure chemical at 28°C, starting titer 10.7 x 106 cells/ml; and pure chemical, cold shock, starting titer 11.3 x 106 cells/ml.  
18 In the pure form the test substance did not induce mitotic chromosome loss; however, almost all of the white colonies scored at the highest concentrations turned out to be respiratory deficient.  The authors concluded that the test substance 
induces mitochondrial mutation under these experimental conditions. 
19  Pentan-2,4-dione (purity 99.2%) was tested for sister chromatid exchange in Chinese hamster ovary (CHO) cells at culture concentrations of 6 to 100 micrograms/ml without metabolic activation and 10 to 300 micrograms/ml with metabolic 
activation. Experiments were carried out in duplicate. In preliminary experiments the appropriate range of test concentrations was determined for which the highest concentration would not kill more than 90% of the treated cells. Cytotoxic effects 
have been reported at concentrations of ≥1 mg/ml, concentrations above 2 mg/ml were lethal. Result: At the highest three doses evaluated for SCE (10, 30 and 100 micrograms/ml in the absence and 30, 100 and 300 in the presence of metabolic 
activation), pentan-2,4-dione produced significant (p<0.001) increases in the incidence of SCE in CHO cells both with and without metabolic activation. The SCE increase was greater without metabolic activation than with metabolic activation. A 
steep dose-response relationship was observed without S9, but not with S9. However, reproducible and statistically significant (p<0.001) increases were apparent in both tests. A remarkably high increase in the incidence of SCEs, which was higher 
than the positive control, was observed at 100 micrograms/ml without metabolic activation..Mitotic inhibition was evident only with the 300 micrograms/ml dose without S9. 
20 Pentan-2,4-dione (purity 99.2 %) was tested in a chromosomal aberration assay in Chinese Hamster Ovary Cells at concentrations of 40–120 micrograms/ml without metabolic activation and 60-140 micrograms/ml with metabolic activation. The 
three highest concentrations (80, 100 and 120 micrograms/ml without metabolic activation and 100, 120 and 140 micrograms/ml with metabolic activation) were analysed for chromosomal damage. Preliminary tests performed to assess effects on 
cell cycle division, indicated that pentan-2,4-dione produced a significant delay in cell division cycle, which was more pronounced in the absence than in the presence of S9. Test concentrations were selected on the basis of cytotoxicity data from 
preliminary experiments. Result: Statistically significant (p>0.001) increases in numbers of chromosome aberrations were observed at the three highest concentrations without S9 activation. However, in the presence of metabolic activation the cells 
tested did not demonstrate increased numbers of chromosome aberrations at any concentrations compared to control values. 
21Standard plate-incorporation method, with and without S9. 
21Modified pre-incubation method, with and without S9. 
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In vivo mutagenicity/genotoxicity data are available for one supporting substance evaluated by the JECFA at the 51th meeting and for one structurally related 
compound (pentan-2,4-dione). Supporting substance is listed in brackets. 
 
 
1 Excessive mortality was observed at 400 and 650 mg/kg dose levels; therefore, these dose levels were replaced with 50 and 100 mg/kg.  
2 Pentan-2,4-dione (purity 99.2 %) was tested in an in vivo Mouse Micronucleus Assay. Swiss Webster Mice (5 animals per sex/dose group) were given i.p. injections of 200, 400 and 650 mg/kg. Peripheral blood was sampled at 30, 48 and 72 hours 
post injection. Results: In a dose-finding study using 579-1200 mg/kg toxicity was observed from 694-1200 mg/kg (20% to 100% mortality) and an LD50 of 808 mg/kg i.p. was found (95 % confidential interval 731.6-889.9 mg/ml). In this study, at 
48 hrs post-injection, PCE/NCE ratio was reduced by 30 % and 23 % below the control levels for male and female animals that received a dose of 694 mg/kg, respectively.In the micronucleus study, the PCE/NCE ratio was determined in the 650 
mg/kg group and in controls. No significant or dose-related decrease in the PCE/NCE ratio for either sex at any of the sample times (slight decrease with dose-related trend seen in females at 30hrs). In contrast, PCE/NCE ratio at 30 hrs was 
increased over control values in males at 400 and 650 mg/kg. A similar effect was not observed at any concentration at 48 hrs. A significant decrease in the PCE/NCE ratio (56.5% of the control) was observed with the positive control. The mean 
percentages of micronucleated PCEs were 0.38 and 0.22 for the vehicle control males and 0.12 and 0.14 for the vehicle control females sampled at 30 and 48 hrs, respectively. Mean percentages of micronucleated PCEs in CP-treated positive 
controls were 2.36 in males and 2.52 in females at 30 hrs post-treatment.At 30 hrs, a statistically significant increase in the incidence of micronucleated PCE was observed in the peripheral blood at 400 and 650 mg/kg. The effect was not dose-
related. The mean percentages of micronucleated PCEs were 1.42 and 0.80 at 400 mg/kg and 1.16 and 0.80 at 650 mg/kg in males and females, respectively. At 48 hours a lower increase in micronucleated PCE than at 30 hrs was found at all 
concentrations tested. As there was no sex-related difference in the micronucleus response between males and females sampled at 48 and 72 hrs post-treatment, male and female values were combined for statistical analysis. A dose-related and 
statistically significant (p<0.001) increase in the incidence of micronuclei was observed at the 48 hrs sample period. A maximum incidence of 0.69 % (3.8 times the vehicle controls) micronucleated PCEs was observed for the highest dose level 
tested. The maximum ratio in the incidences of micronucleated PCEs compared to control was 6.7 (0.80 % at 400 mg/kg at 30 h in females compared to 0.12 % in control females). At 72 hrs the micronucleus response had returned to baseline levels. 
3  Pentan-2,4-dione (purity >98%) was tested in an in vivo Mouse Micronucleus Assay. Swiss Webster Mice (5 animals per sex/dose group) were given i.p injections of 400 and 650 mg/kg. Bone marrow was sampled 6, 24 and 48 hours post-
injection.Results: Serious signs of toxicity were observed in both males and females at 650 mg/kg. Hypoactivity was seen in several males and females at 400 mg/kg. No serious signs of toxicity were observed in animals of either sex after day 1. In 
the micronucleus study, at 6 and 24 hrs a significant (p<0.05) increase in the PCE/NCE ratio over control values was observed at 400 mg/kg in males. No changes in the PCE/NCE ratio was seen in males at 48 hrs in either treatment group and in 
females of either treatment group at any sampling time. The mean percentages of micronucleated PCEs were 0.19, 0.29 and 0.18 for the vehicle control males and 0.20, 0.22 and 0.31 for the vehicle control females sampled at 6, 24 and 48 hrs, 
respectively. At 24 hrs the incidence of micronucleated PCEs was significantly increased in males and females at 400 and 650 mg/kg. The effect was not dose-related. The mean percentages of micronucleated PCEs were 0.81 and 0.97 at 400 mg/kg 
and 1.32 and 0.80 at 650 mg/kg in males and females, respectively. Mean percentages of micronucleated PCEs in CP-treated positive controls at 24 hrs post-treatment were 1.47 and 1.63% in males and females, respectively. The frequency of 
micronucleated PCEs was significantly increased at 24 hrs at 400 mg/kg and at 650 mg/kg, both in males and females. A maximum incidence of 1.32 % (4.6 times the vehicle controls) micronucleated PCEs was observed for the highest dose level 
TABLE IV.5: GENOTOXICITY (IN VIVO)  
Chemical Name [FL-
no] 
Test system Test Object 
 
Route Dose Result Refence Comments 
(Diacetyl [07.052]) In vivo Mouse Micronucleus 
Assay(bone marrow) 
Mouse Oral 
administration 
300, 600, 1200, 2400 
mg/kg;  
300 mg/kg × 4 doses 
Negative (Iwata et al., 1984) Published study in Japanese. Results (i.e. frequencies of PCEs and 
micronucleated PCEs, including positive and negative controls) are 
given in tables. No information can be found on sampling times. 
Validity of the study cannot be evaluated. 
In vivo Mouse Micronucleus 
Assay (bone marrow) 
Mouse Intraperitoneal 
injection 
8, 16, 31, 62, 125, 250, 
500 mg/kg 
Negative (NTP, 1994c) Sampling at 24 hrs. Only summarised results of the study available. 
The PCE/NCE ratio was not reported so it is unclear whether the 
test substance has reached the bone marrow. Relevance of the 
results is limited. 
[Pentan-2,4-dione]  In vivo Mouse Micronucleus 
Assay (peripheral blood) 
Mouse Intraperitoneal 
injection 
200, 400, 650 mg/kg Positive 2 (Guzzie & Morabit, 
1986) 
Sampling at 30, 48, 72 hrs. Toxic effects during the study not 
reported (LD50 of 808 mg/kg). Unpublished valid GLP-study.  
In vivo Mouse Micronucleus 
Assay (bone marrow) 
Mouse Intraperitoneal 
injection 
400, 650 mg/kg Positive  3 (Vergnes & Kubena, 
1994a) 
Sampling at 6, 24, 48 hrs. Toxic effects during the study not 
reported (LD50 of 808 mg/kg).  
Good quality GLP study carried out according to OECD and US 
EPA guidelines. 
In vivo Rat Micronucleus 
Assay  
(bone marrow) 
Rat Intraperitoneal 
injection 
50, 100, 200 (400, 650) 
mg/kg2 
Negative (Vergnes & Kubena, 
1994b) 
Sampling at 6, 24, 48 hrs. Only summarised results of the study 
available.  
Unpublished valid study carried out according to EPA standards. 
Due to the lack of an effect on the PCE/NCE ratio it is unclear 
whether the test substance has reached the bone marrow. 
Relevance of the results is limited. 
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tested. This was also the maximum ratio in the incidences of micronucleated PCEs compared to control (1.32 % at 650 mg/kg at 24 h in males compared to 0.29 % in control males). No significant increase of micronucleated PCEs was observed at 6 
and 48 hrs at 400 mg/kg and at 650 mg/kg in either sex.  
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 ABBREVIATIONS 
ADI  Acceptable Daily Intake 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IP   Intrapertoneal 
IR   Infrared spectroscopy 
IV   Intravenous 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50%; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
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SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDP  Uridine DiPhosphate 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
